HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

belagenpumatucel L

a TGF-beta2 antisense gene-modified allogeneic tumor cell vaccine that inhibits TGF-beta2; in phase II clinical trials for treatment of non-small-cell lung cancer
Also Known As:
belagenpumatucel-L; lucanix
Networked: 19 relevant articles (2 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Vansteenkiste, Johan: 3 articles (03/2014 - 07/2011)
2. Giaccone, G: 2 articles (11/2015 - 11/2015)
3. Fakhrai, H: 2 articles (11/2015 - 08/2009)
4. Nemunaitis, J: 2 articles (11/2015 - 08/2009)
5. Raez, Luis E: 2 articles (09/2014 - 10/2011)
6. Moses, S C: 1 article (11/2015)
7. Juhász, E: 1 article (11/2015)
8. Tan, M: 1 article (11/2015)
9. Davis, C S: 1 article (11/2015)
10. Bazhenova, L A: 1 article (11/2015)

Related Diseases

1. Melanoma (Melanoma, Malignant)
2. Lung Neoplasms (Lung Cancer)
3. Neoplasms (Cancer)
4. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
5. Circulating Neoplastic Cells

Related Drugs and Biologics

1. Antigens
2. Vaccines
3. Epidermal Growth Factor (EGF)
4. talactoferrin alfa
5. Mucin-1 (CA 15-3 Antigen)
6. Toll-Like Receptors (Toll-Like Receptor)
7. ipilimumab
8. L-BLP25
9. TG4010
10. belagenpumatucel L

Related Therapies and Procedures

1. Immunotherapy
2. Drug Therapy (Chemotherapy)
3. Stents